Aiforia Technologies Oyj Sees Clinical Growth Surge

Aiforia Technologies Oyj reported strong growth in its clinical segment for the second half of 2025. Net sales rose by 45% year-on-year to €2.1 million, with the clinical segment alone experiencing a 68% increase to €1.5 million. This growth stemmed from an increased share of wallet among existing clients and new clinical tender wins.

Geographically, 73% of revenue now comes from Europe, a significant rise from previous figures, as the company expands its European client base. Profitability improved as EBITDA reduced to € -3.0 million compared to € -4.0 million, aided by operational leverage and personnel cost reductions.

Aiforia ended the year with a cash position of €9.5 million. The company expects continued growth, aiming to expand its clinical client base significantly by 2030, supporting a positive outlook for upcoming years.